Inch­ing clos­er to block­buster sta­tus, Seat­tle Ge­net­ics gets fourth FDA win for Ad­cetris

Seat­tle Ge­net­ics $SGEN has bagged an­oth­er ap­proval for its flag­ship ther­a­py Ad­cetris — now the fourth in­di­ca­tion for the can­cer drug.

The FDA ap­proved Ad­cetris (bren­tux­imab ve­dotin) to treat the most com­mon sub­types of cu­ta­neous T-cell lym­phoma: pri­ma­ry cu­ta­neous anaplas­tic large cell lym­phoma (pcAL­CL) and CD30-ex­press­ing my­co­sis fun­goides (MF). The green light came more than a month be­fore the PDU­FA date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER